Compare Beyond Meat Inc (BYND) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Recursion Pharmaceuticals Inc — how do they compare? Beyond Meat Inc trades at $0.63 (market cap $320.23M), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.6× Beyond Meat Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | RXRX | |
|---|---|---|
Market Cap | $320.23M | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $4.28 | $6.79 |
52-Week Low | $0.52 | $2.84 |
Enterprise Value | $630.23M | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.63, down 4.15% today, reflecting persistent bearish sentiment amid declining revenues and negative cash flow from operations. The stock shows technical weakness with moving averages signaling bearish momentum, though oversold RSI conditions suggest potential for near-term bounce. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 and Q3 2025 missing estimates. The company continues expansion efforts with new product launches including Beyond Steak Filet and protein beverages.
Investment outlook remains challenging with 57% analyst sell ratings and negative operating cash flow of $145M in 2025. While valuation metrics appear attractive with P/S of 0.65 and EV/EBITDA of 2.08, ongoing revenue declines and reliance on financing activities for liquidity pose significant risks. The turnaround strategy through product diversification faces execution challenges in a competitive plant-based protein market.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
